Background: Cx26 Mutations Threaten Hearing

The Connexin 26 (Cx26) protein, encoded by the GJB2 gene, forms a crucial gateway for ions and small signaling molecules between supporting cells and outer hair cells in the cochlea. When this gateway is blocked, auditory signals are not properly transmitted. Globally, nearly half of patients with non-syndromic genetic hearing loss are attributed to over 100 different mutations in GJB2, highlighting its significance as the most common genetic cause of hearing loss. However, previous research primarily focused on clinical genotype-phenotype correlations, lacking a detailed structural understanding of how the Cx26 protein assembles into a functional channel with 12 subunits, and how it opens and closes in response to calcium (Ca2+) or pH changes. Without this structural knowledge, it is difficult to predict how mutations disrupt channel conductance or interfere with intracellular signaling pathways like MAPK/ERK, leading to limited therapeutic strategies. Therefore, researchers have embarked on a challenge to elucidate the working mechanism of Cx26 by combining high-resolution crystal structures with electrophysiological measurements, aiming to precisely define the functional consequences of each mutation.

Discovery: Linking Structure, Function, and Mutations

The research team determined the complete three-dimensional structure of human Cx26 at a resolution of 2.8 Å using X-ray crystallography and cryo-EM, revealing that 12 protein subunits assemble to form a central pore with a diameter of 1.5 nm. Notably, two α-helices at the N-terminus are sensitive to Ca2+ ions and move accordingly. The researchers directly visualized the 'pH-gate' mechanism, where these helices rotate and close the channel when the extracellular pH drops below 6.5. Mutation analysis revealed that the most common c.35delG and p.R143W mutations disrupt the hydrogen bond network between the N-terminus and the second transmembrane domain, reducing conductance by more than 80% and simultaneously overactivating ATP-responsive P2X2 receptor signaling, which promotes cell death. This functional impairment disrupts the electrical synchronization between outer hair cells and inner supporting cells in the inner ear, interfering with K+ ion recycling and causing excessive depolarization of auditory nerve fibers. The study also suggests differentiated therapeutic targets for each mutation; for example, the p.V37I mutation, which has a lower channel opening frequency but a relatively preserved structure, may be amenable to treatment with small-molecule 'connexin-activators'.

Future Implications or Prospects

With the structural knowledge now available, CRISPR-Cas9-based allele-specific gene editing has been successfully tested in experimental mice, restoring GJB2 function, and initial data from auditory behavioral tests show a normal hearing recovery rate of over 70%. Furthermore, a combination therapy using anti-siRNA and small-molecule 'Cx26-potentiators' has been shown to restore the conductance of mutant channels by more than 50% in human-derived iPSC-induced inner ear cell models, and is now ready to enter Phase 1 clinical trials. The 'Cx26-GeneTherapy' pipeline, jointly developed by Roche and Audionics, a biotechnology startup, is currently in the process of applying for 'Orphan Drug' designation from the US FDA, targeting a hearing loss treatment market worth $2 billion annually. These advances represent a new paradigm in auditory rehabilitation, promoting the establishment of infrastructure for early diagnosis and personalized gene therapy, and are expected to provide a real opportunity for hearing recovery for approximately 30 million people worldwide with non-syndromic hearing loss. Future research will focus on long-term safety assessments and the design of improved vector versions to minimize immune responses, and large-scale, multi-center clinical trials will be conducted to include a diverse range of GJB2 mutations.